Wiskott–Aldrich syndrome

Advancements in reproductive medicine available at Shady Grove Fertility (SGF) can reduce the inheritance of genetic diseases like breast cancer

Thursday, October 14, 2021 - 1:45pm

Individuals and couples with known genetic diseases can turn to Shady Grove Fertility (SGF) to undergo in vitro fertilization (IVF) with preimplantation genetic testing for monogenic/single gene defects(PGT-M) to reduce the risk of passing genetic mutations to future offspring.

Key Points: 
  • Individuals and couples with known genetic diseases can turn to Shady Grove Fertility (SGF) to undergo in vitro fertilization (IVF) with preimplantation genetic testing for monogenic/single gene defects(PGT-M) to reduce the risk of passing genetic mutations to future offspring.
  • Additionally, patients at risk for dominant gene mutations, such as breast cancer or inherited forms of colon cancer, can have individualized testing for these diseases.
  • While Rose is not a carrier for the breast cancer gene, she is a carrier of a rare X-linked genetic mutation called Wiskott-Aldrich syndrome.
  • We are so fortunate to live in a world where we can now reduce the inheritance of deadly genetic diseases via IVF.

BlueCross Will Cover Costs for COVID-19 Booster

Tuesday, September 14, 2021 - 8:32pm

We want to ensure those needing a COVID-19 booster understand their costs are covered, said Dr. Andrea Willis, chief medical officer for BlueCross.

Key Points: 
  • We want to ensure those needing a COVID-19 booster understand their costs are covered, said Dr. Andrea Willis, chief medical officer for BlueCross.
  • For commercial Blue Network S, P and L members, BlueCross will cover the cost of the fees associated with receiving the COVID-19 booster.
  • Medicare Advantage, BlueCare Tennessee and BlueCare Plus Tennessee members will also be able to get a booster without any out-of-pocket costs.
  • The BlueCross BlueShield of Tennessee Foundation, Inc. is a 501(c)(3) not-for-profit corporation organized to promote the philanthropic mission of BlueCross BlueShield of Tennessee.

ADMA Biologics Reports Record Second Quarter 2021 Financial Results and Highlights Recent Progress and Accomplishments

Wednesday, August 11, 2021 - 9:05pm

RAMSEY, N.J. and BOCA RATON, Fla., Aug. 11, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today reported financial results for the three months ended June 30, 2021, its fiscal second quarter, and provided an overview of recent progress and accomplishments.

Key Points: 
  • ET
    RAMSEY, N.J. and BOCA RATON, Fla., Aug. 11, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (ADMA or the Company), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today reported financial results for the three months ended June 30, 2021, its fiscal second quarter, and provided an overview of recent progress and accomplishments.
  • ADMA continues to achieve milestones and execute on its commercial and operational strategies as evidenced by the strong second quarter financial results and regulatory successes.
  • Select Second Quarter 2021 Achievements & Recent Corporate Developments:
    Continued Commercial Execution: Achieved second quarter 2021 total revenues of $17.8 million, compared to $7.8 million for the second quarter of 2020, reflecting a 129% increase.
  • ADMA will host a conference call today, August 11, 2021, at 4:30 p.m. Eastern Time, to discuss the fiscal second quarter 2021 financial results and recent corporate updates.